Jill M. Quigley

Jill M. Quigley is currently the Chief Operating Officer at Passage Bio, Inc., a biotechnology company developing gene therapies for the treatment of rare, monogenic, central nervous system diseases. Prior to joining Passage Bio, she served as Chief Executive Officer and General Counsel of Nutrinia Ltd., a biopharmaceutical company focused on the treatment of rare conditions of the gastrointestinal tract. Before joining Nutrinia, Ms. Quigley served as Senior Counsel of NPS Pharmaceuticals, Inc., a biotechnology company focused on developing treatments for rare diseases, which was acquired by Shire plc in March 2015. Ms. Quigley previously served as Corporate Counsel for Pharmasset, Inc., a pharmaceutical company acquired by Gilead Sciences in 2011. She also worked as an Associate with the law firm of Dechert LLP and later served as Assistant Corporate Counsel for Integra Life Sciences Holdings Corporation. Ms. Quigley holds a B.A. in Communications, Legal Institutions, Economics & Government (CLEG) from American University and a J.D. from Rutgers School of Law.